Trial Information

[Guest guest]

Trial InformationSummary: A Phase II study to look at a drug called BMS 188667 given to patients with Relapsing Remitting MS.BMS 188667 is an experimental drug that is not approved by the Food and Drug Administration (FDA). This is being used for the first time in patients with MS. Studies suggest this drug blocks activation of a special cell called T cells. This is a 10-month double blind placebo-controlled trial. This means that neither the subject or study doctor will know about what drug or a placebo(a drug without active ingredients) subjects are receiving.Subjects will receive 9 intravenous (into the vein) infusions and 10 MRI (Magnetic Resonance Imaging) scans of the brain. There are 16 visits over the course of the study. Dr. Fred Lublin is the physician invloved with this research project.No Compensation ProvidedPatient Inclusion/Exclusion Criteria:* Relapsing Remitting MS* Males and Females 18-55 Years old* 1 Relapse in past 2 years* Must Meet Eligibility Criteria* Current therapy to treat MS (i.e., interferons or glatiramer acetate)* Pregnancy, breast feeding or desire to become pregnantContact:Michele Weber, Research CoordinatorMount Sinai Medical CenterOne Gustave L. Levy PlaceNew York, NY 10029Telephone: 212-241-4264Fax: 212-241-9771Email: michele.weber@... Provided byMapQuest